• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Results from 2021 Managed Healthcare Executive® Pharmacy Survey

Publication
Slideshow
MHE PublicationMHE June 2021
Volume 31
Issue 6

Respondents upbeat about COVID-19 vaccination. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.

MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.

Answers to our questions about the COVID-19 vaccination show a fairly high degree of optimism among the respondents. Most (63%) felt herd immunity would be reached by the end of October. Only 18% were concerned about the current vaccines not protecting against the variant. Just under half (45%) expect one more vaccine to be available in the U.S. this year, bringing the total to four.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.